What is TC Biopharm's stock price target for 2024?

0 equities research analysts have issued 12-month price targets for TC Biopharm's shares. Their TCBP share price targets range from $1,400.00 to $1,400.00. On average, they anticipate the company's share price to reach $1,400.00 in the next twelve months. This suggests a possible upside of 96,458.4% from the stock's current price. View analysts price targets for TCBP or view top-rated stocks among Wall Street analysts .

How have TCBP shares performed in 2024?

TC Biopharm's stock was trading at $3.17 at the start of the year. Since then, TCBP stock has decreased by 54.3% and is now trading at $1.4499. View the best growth stocks for 2024 here .

Are investors shorting TC Biopharm?

TC Biopharm saw a decline in short interest in March. As of March 31st, there was short interest totaling 204,500 shares, a decline of 68.0% from the March 15th total of 638,700 shares. Based on an average trading volume of 4,520,000 shares, the days-to-cover ratio is presently 0.0 days. View TC Biopharm's Short Interest .

When is TC Biopharm's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024. View our TCBP earnings forecast .

When did TC Biopharm's stock split?

TC Biopharm shares reverse split on Friday, December 15th 2023. The 1-20 reverse split was announced on Friday, December 15th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, December 15th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

When did TC Biopharm IPO?

TC Biopharm (TCBP) raised $17 million in an initial public offering (IPO) on Friday, February 11th 2022. The company issued 4,100,000 shares at a price of $4.25 per share. EF Hutton served as the underwriter for the IPO.

How do I buy shares of TC Biopharm?

Shares of TCBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:TCBP

TC Biopharm (TCBP) Stock Price, News & Analysis

→ Could Bitcoin Literally FORCE This Crypto To Rocket Up? (From Paradigm Press) (Ad)

Free TCBP Stock Alerts

$1.49

+0.14 (+10.39%)

(As of 10:48 AM ET)

Compare

Today's Range: $1.37
▼
$1.52
50-Day Range: $1.03
▼
$1.95
52-Week Range: $0.85
▼
$32.60

Volume: 105,861 shs
Average Volume: 3.94 million shs
Market Capitalization: $1.01 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $1,400.00

Get TC Biopharm alerts:

TC Biopharm MarketRank™ Stock Analysis

Analyst Rating: 0.00 Rating Score
Upside/Downside: 96,458.4% Upside
$1,400.00 Price Target
Short Interest: Healthy
30.07% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.43 out of 5 stars

2.0

Analyst's Opinion

Amount of Analyst Coverage
TC Biopharm has received no research coverage in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
30.07% of the outstanding shares of TC Biopharm have been sold short.
Short Interest Ratio / Days to Cover
TC Biopharm has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in TC Biopharm has recently decreased by 67.98%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
TC Biopharm does not currently pay a dividend.
Dividend Growth
TC Biopharm does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for TCBP.

0.6

News and Social Media Coverage

Search Interest
Only 8 people have searched for TCBP on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.
MarketBeat Follows
4 people have added TC Biopharm to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, TC Biopharm insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.05% of the stock of TC Biopharm is held by insiders.
Percentage Held by Institutions
Only 16.25% of the stock of TC Biopharm is held by institutions.

0.6

Earnings and Valuation

Price to Book Value per Share Ratio
TC Biopharm has a P/B Ratio of 0.29. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About TC Biopharm Stock (NASDAQ:TCBP)

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.

TCBP Stock Price History

30 days | 90 days | 365 days | Advanced Chart

TCBP Stock News Headlines

April 6, 2024 | uk.investing.com

TC BioPharm eyes expansion with CAR-NK technology LOI

April 4, 2024 | msn.com

Hyosung invests $1bn in green raw materials for ‘bio-spandex’

April 18, 2024 | Crypto 101 Media (Ad)

[Urgent!] Generational Wealth Gameplan

A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.

April 4, 2024 | marketwatch.com

TC BioPharm Shares Rise 63% After Letter Intent to Buy Cancer Therapy Assets

April 4, 2024 | investorplace.com

Why Is TC Biopharm (TCBP) Stock Up 78% Today?

April 4, 2024 | markets.businessinsider.com

TC BioPharm Enters Non-Binding Letter Of Intent For Acquisition Of NK Platform Technologies

April 4, 2024 | finance.yahoo.com

TCBP Announces Execution of Non-Binding Letter of Intent for Acquisition of NK Platform Technologies

April 2, 2024 | prnewswire.com

TCBP Increasing Treatment Capacity with Expanded Manufacturing Process

April 18, 2024 | Crypto 101 Media (Ad)

[Urgent!] Generational Wealth Gameplan

A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.

March 19, 2024 | finance.yahoo.com

TCBP Adjourns General Meeting Until a Later Date

March 18, 2024 | finance.yahoo.com

TCBP Announces Exercise of Series D Warrants For Cash

March 6, 2024 | msn.com

BeyondSpring, enVVeno Medical, Aptorum Group among healthcare movers

March 1, 2024 | finance.yahoo.com

Bryan Kobel, CEO of TCBP, Appears on Nationally Syndicated "The Big Biz Show"

February 27, 2024 | finance.yahoo.com

/C O R R E C T I O N -- TC BioPharm/

February 27, 2024 | prnewswire.com

TCBP Announces Shareholder Update Call on March 5th 2024

February 22, 2024 | benzinga.com

TC BioPharm (Holdings) Stock (NASDAQ:TCBP), Short Interest Report

February 22, 2024 | msn.com

Ocugen, Community Health Systems among healthcare movers

February 22, 2024 | finance.yahoo.com

TCBP Announces MHRA Acceptance of Amendment for ACHIEVE UK Trial

February 22, 2024 | prnewswire.com

TCBP Announces MHRA Acceptance of Amendment for ACHIEVE UK Trial

February 15, 2024 | finance.yahoo.com

TC BioPharm Management to Participate at Upcoming 7th CAR-TCR Summit Europe

February 15, 2024 | prnewswire.com

TC BioPharm Management to Participate at Upcoming 7th CAR-TCR Summit Europe

February 14, 2024 | finance.yahoo.com

TCBP Provides Shareholder Update and Highlights Upcoming Milestones

February 14, 2024 | prnewswire.com

TCBP Provides Shareholder Update and Highlights Upcoming Milestones

February 12, 2024 | seekingalpha.com

VUZI, TCBP and MANU among pre-market losers

February 9, 2024 | msn.com

BioXcel Therapeutics, Synlogic among healthcare movers

February 6, 2024 | msn.com

European Equities Traded in the US as American Depositary Receipts Higher in Tuesday Trading

January 29, 2024 | finance.yahoo.com

TC BioPharm Chief Executive Officer, Bryan Kobel Featured on 'The Big Biz Show'

See More Headlines

Receive TCBP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TC Biopharm and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/18/2024
Next Earnings (Estimated): 5/06/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:TCBP
CUSIP: N/A
CIK: 1872812
Web: www.tcbiopharm.com
Phone: 44-14-1433-7557
Fax: N/A
Employees: 60
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $1,400.00
High Stock Price Target: $1,400.00
Low Stock Price Target: $1,400.00
Potential Upside/Downside: +103,603.7%
Consensus Rating
Rating Score (0-4): 0.00
Research Coverage: 0 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: 0.56
Current Ratio: 1.20
Quick Ratio: 1.20

Sales & Book Value

Annual Sales: $4.76 million
Price / Sales: 0.19
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.94 per share
Price / Book: 0.27

Miscellaneous

Outstanding Shares: 680,000
Free Float: 677,000
Market Cap: $918,000.00
Optionable: Not Optionable
Beta: 0.32

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

Mr. Bryan L. Kobel (Age 45)
CEO & Director
Mr. Martin E. Thorp (Age 72)
CFO & Director
Mr. Christopher Camarra
Executive Vice President of Communications
Dr. Lauren Bor Ph.D.
Head of Commercial Development Division

Key Competitors

View All Competitors

Institutional Ownership

Armistice Capital LLC
Sold 223,500 shares on 2/13/2024
Ownership: 10.882%

View All Institutional Transactions

TCBP Stock Analysis - Frequently Asked Questions

What is TC Biopharm's stock price target for 2024?: 0 equities research analysts have issued 12-month price targets for TC Biopharm's shares. Their TCBP share price targets range from $1,400.00 to $1,400.00. On average, they anticipate the company's share price to reach $1,400.00 in the next twelve months. This suggests a possible upside of 96,458.4% from the stock's current price.
View analysts price targets for TCBP or view top-rated stocks among Wall Street analysts.
How have TCBP shares performed in 2024?: TC Biopharm's stock was trading at $3.17 at the start of the year. Since then, TCBP stock has decreased by 54.3% and is now trading at $1.4499.
View the best growth stocks for 2024 here.
Are investors shorting TC Biopharm?: TC Biopharm saw a decline in short interest in March. As of March 31st, there was short interest totaling 204,500 shares, a decline of 68.0% from the March 15th total of 638,700 shares. Based on an average trading volume of 4,520,000 shares, the days-to-cover ratio is presently 0.0 days.
View TC Biopharm's Short Interest.
When is TC Biopharm's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024.
View our TCBP earnings forecast.

When did TC Biopharm's stock split?: TC Biopharm shares reverse split on Friday, December 15th 2023. The 1-20 reverse split was announced on Friday, December 15th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, December 15th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.
When did TC Biopharm IPO?: TC Biopharm (TCBP) raised $17 million in an initial public offering (IPO) on Friday, February 11th 2022. The company issued 4,100,000 shares at a price of $4.25 per share. EF Hutton served as the underwriter for the IPO.
How do I buy shares of TC Biopharm?: Shares of TCBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TCBP) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

TC Biopharm (TCBP) Stock Price, News & Analysis

TC Biopharm MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Amount of Analyst Coverage

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Dividend Yield

Dividend Growth